A Study of LY3023414 in Participants With Advanced Cancer

I6A-MC-CBBA -

The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Cancer
What the trial is testing?
Letrozole, Midazolam, Abemaciclib, Samotolisib, Pemetrexed, Fulvestrant, Cisplatin
Could I receive a Placebo?
No
Enrollment Goal
156
Trial Dates
Jul 31, 2012 - Feb 2, 2022
How long will I be in the trial?
Your participation could last up to 42 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant in part B4 must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapy

  • Participant in part B6 must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathway

  • Participant in part B7 must have HR+ abd HER2- breast cancer

  • Participant may need to undergo a biopsy dependent upon which arm of the study you are in

  • Participant must be able to swallow capsules

  • Participant must be reliable and willing to make themselves available for the duration of the study and be willing to follow study procedures

Participants Must Not:

  • Participant must not have known acute or chronic leukemia

  • Participant must not have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.